

Pnina Fishman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2222932/publications.pdf>

Version: 2024-02-01

47
papers

2,656
citations

218381
26
h-index

276539
41
g-index

47
all docs

47
docs citations

47
times ranked

2238
citing authors

#	ARTICLE	IF	CITATIONS
1	Editorial: targeting aberrant hepatic inflammation for treatment of non-alcoholic steatohepatitis—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 485-486.	1.9	0
2	Drugs Targeting the A3 Adenosine Receptor: Human Clinical Study Data. <i>Molecules</i> , 2022, 27, 3680.	1.7	18
3	A3 adenosine receptor allosteric modulator CF602 reverses erectile dysfunction in a diabetic rat model. <i>Andrologia</i> , 2022, 54, .	1.0	3
4	Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial. <i>Cancers</i> , 2021, 13, 187.	1.7	25
5	Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1405-1415.	1.9	19
6	Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 491-497.	2.0	28
7	The A3 adenosine receptor agonist, namodenoson, ameliorates non-alcoholic steatohepatitis in mice. <i>International Journal of Molecular Medicine</i> , 2019, 44, 2256-2264.	1.8	25
8	Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A3 Adenosine Receptor Agonist Piclidenoson. <i>Journal of Immunology Research</i> , 2018, 2018, 1-8.	0.9	25
9	Adenosine Receptors and Current Opportunities to Treat Cancer. , 2018, , 543-555.		7
10	A3 adenosine receptor agonist, CF102, protects against hepatic ischemia/reperfusion injury following partial hepatectomy. <i>Molecular Medicine Reports</i> , 2016, 14, 4335-4341.	1.1	24
11	The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 2359-2362.	1.0	54
12	Treatment of Plaque-Type Psoriasis With Oral CF101: Data from a Phase II/III Multicenter, Randomized, Controlled Trial. <i>Journal of Drugs in Dermatology</i> , 2016, 15, 931-8.	0.4	28
13	A3 Adenosine Receptor Allosteric Modulator Induces an Anti-Inflammatory Effect: In Vivo Studies and Molecular Mechanism of Action. <i>Mediators of Inflammation</i> , 2014, 2014, 1-8.	1.4	27
14	CF102 for the Treatment of Hepatocellular Carcinoma: A Phase I/II, Open-Label, Dose-Escalation Study. <i>Oncologist</i> , 2013, 18, 25-26.	1.9	78
15	Targeting the A3 adenosine receptor for glaucoma treatment (Review). <i>Molecular Medicine Reports</i> , 2013, 7, 1723-1725.	1.1	23
16	Pharmacological and therapeutic effects of A3 adenosine receptor agonists. <i>Drug Discovery Today</i> , 2012, 17, 359-366.	3.2	193
17	Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101. <i>International Journal of Molecular Medicine</i> , 2011, 28, 727-31.	1.8	44
18	Treatment of Dry Eye Syndrome with Orally Administered CF101. <i>Ophthalmology</i> , 2010, 117, 1287-1293.	2.5	78

#	ARTICLE	IF	CITATIONS
19	Rheumatoid Arthritis: History, Molecular Mechanisms and Therapeutic Applications. , 2010, , 291-298.		3
20	Agonists and Antagonists: Molecular Mechanisms and Therapeutic Applications. , 2010, , 301-317.		3
21	Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. Journal of Rheumatology, 2008, 35, 41-8.	1.0	106
22	The anti-inflammatory effect of A ₃ adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opinion on Investigational Drugs, 2007, 16, 1601-1613.	1.9	79
23	Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level. Journal of Rheumatology, 2007, 34, 20-6.	1.0	68
24	Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression. Arthritis Research and Therapy, 2006, 8, R169.	1.6	48
25	The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Research and Therapy, 2006, 8, R33.	1.6	80
26	CF101, An Agonist to the A3 Adenosine Receptor, Enhances the Chemotherapeutic Effect of 5-Fluorouracil in a Colon Carcinoma Murine Model. Neoplasia, 2005, 7, 85-90.	2.3	40
27	Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. Journal of Rheumatology, 2005, 32, 469-76.	1.0	72
28	The A3 Adenosine Receptor Is Highly Expressed in Tumor versus Normal Cells. Clinical Cancer Research, 2004, 10, 4472-4479.	3.2	420
29	An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 β and NF- κ B. Oncogene, 2004, 23, 2465-2471.	2.6	93
30	Modulation of the A3 adenosine receptor by low agonist concentration induces antitumor and myelostimulatory effects. Drug Development Research, 2003, 58, 386-389.	1.4	18
31	A3 Adenosine Receptor Activation in Melanoma Cells. Journal of Biological Chemistry, 2003, 278, 42121-42130.	1.6	91
32	Pharmacology and Therapeutic Applications of A3 Receptor Subtype. Current Topics in Medicinal Chemistry, 2003, 3, 463-469.	1.0	84
33	Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist. Anticancer Research, 2003, 23, 2077-83.	0.5	70
34	A3 adenosine receptor as a target for cancer therapy. Anti-Cancer Drugs, 2002, 13, 437-443.	0.7	114
35	Suppression of experimental zymosan-induced arthritis by intraperitoneal administration of adenosine. Drug Development Research, 2002, 57, 182-186.	1.4	6
36	Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. Oncogene, 2002, 21, 4060-4064.	2.6	97

#	ARTICLE	IF	CITATIONS
37	IVIg to prevent tumor metastases (Review). International Journal of Oncology, 2002, 21, 875-80.	1.4	11
38	The A3 Adenosine Receptor as a New Target for Cancer Therapy and Chemoprotection. Experimental Cell Research, 2001, 269, 230-236.	1.2	108
39	Differential effect of adenosine on tumor and normal cell growth: Focus on the A3 adenosine receptor. Journal of Cellular Physiology, 2001, 186, 19-23.	2.0	108
40	Involvement of Wnt signaling pathway in murine medulloblastoma induced by human neurotropic JC virus. Oncogene, 2001, 20, 4864-4870.	2.6	53
41	Adenosine acts as a chemoprotective agent by stimulating G-CSF production: A role for A1 and A3 adenosine receptors. Journal of Cellular Physiology, 2000, 183, 393-398.	2.0	55
42	Oral administration of muscle derived small molecules inhibits tumor spread while promoting normal cell growth in mice. Clinical and Experimental Metastasis, 1999, 17, 531-535.	1.7	9
43	Autoantibodies to tyrosinase. , 1997, 79, 1461-1464.		60
44	Autoantibodies to tyrosinase. , 1997, 79, 1461.		2
45	Reactivity to tyrosinase: Expression in cancer (melanoma) and autoimmunity (vitiligo). Human Antibodies, 1996, 7, 151-156.	0.6	16
46	Aspirin-Interleukin-3 Interrelationships in Patients With Anti-Phospholipid Syndrome. American Journal of Reproductive Immunology, 1996, 35, 80-84.	1.2	34
47	Chloramphenicol Induced Inhibition of Platelet Protein Synthesis: <i>in Vitro</i> and <i>in Vivo</i> Studies. British Journal of Haematology, 1976, 33, 53-59.	1.2	9